GEMTESA® (Vibegron) is an oral medication indicated for the treatment of overactive bladder (OAB) with signs of urge urinary incontinence (UUI), urgency, and urinary frequency in adults. GEMTESA® is a selective beta-3 adrenergic agonist which activates beta-3 receptors. This binding results in bladder muscle relaxation, increasing bladder capacity, resulting in reduced symptoms of OAB.
This animation introduces OAB, the causes of this condition. Using eye-catching visuals, the action of GEMTESA® is explored, highlighting Urovant’s intelligent drug design and three key differentiators. The animation also highlights the action of GEMTESA® in comparison to other anticholinergic treatments which target M3 (muscarinic) receptors. Infographics have also been incorporated for the engagement of data visualization.
This medical animation can be found on the homepage of the Urovant medical affairs website. The video is intended for use by US Healthcare professionals (HCPs). The look and feel of the animation are consistent with Urovant’s branding, helping create a strong visual identity.
18 окт 2021
